Price cut unlocks NICE nod for Perjeta in post-surgery breast cancerRoche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer Share XPrice cut unlocks NICE nod for Perjeta in post-surgery breast cancerhttps://pharmaphorum.com/news/price-cut-unlocks-nice-nod-for-perjeta-in-post-surgery-breast-cancer/
Pharma companies clear the R&D decks in Q4The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as Share XPharma companies clear the R&D decks in Q4https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/
R&D roundup: the ups and downs of CRISPR and Alzheimer’sWhile the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm Share XR&D roundup: the ups and downs of CRISPR and Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/
Roche seeks Kadcyla boost to fend off Herceptin biosimilarsAs biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer Share XRoche seeks Kadcyla boost to fend off Herceptin biosimilarshttps://pharmaphorum.com/news/roche-seeks-new-kadcyla-indication/
The future of patient valueAhead of the 2019 eyeforpharma Barcelona conference, we asked speaker and awards judge Heather Moses – head of Share XThe future of patient valuehttps://pharmaphorum.com/views-analysis-patients/the-future-of-patient-value/
Roche cancels two phase III Alzheimer’s trialsRoche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim Share XRoche cancels two phase III Alzheimer’s trialshttps://pharmaphorum.com/news/roche-cancels-two-phase-iii-alzheimers-trials/
Genentech brings back Alexander Hardy to take CEO positionRoche has filled the open CEO position at Genentech with Alexander Hardy, a veteran of the subsidiary. The Share XGenentech brings back Alexander Hardy to take CEO positionhttps://pharmaphorum.com/news/genentech-brings-back-alexander-hardy-ceo-position/
Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech rolesThree more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore Share XEx-Roche, Novartis, AstraZeneca leaders appointed to biotech roleshttps://pharmaphorum.com/news/ex-roche-novartis-astrazeneca-leaders-appointed-to-biotech-roles/
Mycenax’s Actemra biosimilar edges closer to approvalMycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase Share XMycenax’s Actemra biosimilar edges closer to approvalhttps://pharmaphorum.com/news/mycenaxs-actemra-biosimilar-edges-closer-to-approval/
